ScheBo® • Biotech AG

Netanyastrasse 3
35394 Giessen
Germany

ScheBo® • Biotech AG

ScheBo®• Biotech AG is an innovative biotech company that is active in the fields of development, production and marketing of diagnostics and drug development.

ScheBo®• Biotech AG is developing novel cancer therapies for the treatment of various solid tumours and their metastases.

ScheBo®• Biotech AG was founded by the biochemists and molecular biologists Ursula Scheefers-Borchel, Ph.D., and Hans Scheefers, Ph.D. Continuous innovation, strong customer focus and creative problem solving have made ScheBo®• Biotech AG a worldwide leading manufacturer of unique products.

ScheBo®• Biotech AG

- independent
- worldwide distribution network
- exclusive and superior technologies and products
- innovative and unique clinical diagnostic products
- international research network

Human Diagnostics

Gastroenterology
Oncology
Paediatrics

Veterinary Diagnostics

Gastroenterology

Food Analysis

BSE risk assessment

ScheBo® • Biotech AG

Head office

Netanyastrasse 3
35394 Giessen
Germany

Phone ++49(0)641-4996-0
Fax ++49(0)641-4996-77

UK & Republic of Ireland

P.O. Box 6359
Basingstoke RG22 4WE
United Kingdom

Phone ++44(0)1256-477259
Fax ++44(0)1256-327889

www.schebo.com

ScheBo® • Biotech AG

ScheBo® • Tumor M2-PK™

EDTA Plasma Test

Detects a Metabolic State
Specific for a Variety of Tumors

Tumor Metabolic Marker

Gastrointestinal Cancer
Oesophageal Cancer
Lung Cancer
Breast Cancer
Renall Cell Carcinoma

a new era in life science

ScheBo® • Tumor M2-PK™

EDTA Plasma Test



- Detects a Metabolic State Specific for a Variety of Tumors
- The only Tumor Metabolic Marker world wide
- Patient Follow-Up
- Early Detection of Relapses and Metastasis
- Reflecting Disease Activity and Sensitivity to Chemo-therapy in Solid Tumors

The majority of human tumors strongly overexpress an isoform of the glycolytic enzyme pyruvate kinase, the type tumor M2. This isoenzyme is released from tumor cells and is quantitatively detectable in body fluids. The concentration of the type tumor M2 isoenzyme indicates a metabolic switch turning normal cells into tumor cells. It highly correlates with the malignancy of cancer (staging) and it is independent from the histological grading.

This novel type of marker for malignancies is called Tumor M2-PK and is the only tumor metabolic marker so far. ScheBo® • Biotech AG developed a highly sensitive enzyme-linked immunosorbent assay (ELISA) which allows the quantitative measurement of Tumor M2-PK in EDTA plasma. The test is based on two monoclonal antibodies which specifically react with Tumor M2-PK and do not cross react with the other isoforms of pyruvate kinase (Typ L, R, M1 and M2). As Tumor M2-PK is a highly tumor specific protein and shows no organ specificity it may be the marker of choice for a variety of tumors.

Tumor M2-PK gives additional information that is generally not provided by classical tumor markers which reflect tumor burden.

Main Indications

- Complementary Investigations in the Diagnosis of Cancer
- Monitoring Response to Therapy
- Early Detection of Relapse
- Early Detection of Metastasis
- Monitoring of Tumor Agressiveness

Diagnostic Support and Patient Follow-Up

- Colorectal Cancer
- Gastric Cancer
- Oesophageal Carcinoma
- Lung Cancer
- Breast Cancer
- Pancreatic Cancer

Diagnostics

Main Advantages

Tumor M2-PK detects a metabolic state highly specific for a variety of tumors. Its superior usefulness was demonstrated in diagnosis and monitoring of different cancer types. First reliable tumor marker for renal cell carcinoma.
High sensitivity and high specificity.

Method of Detection

Sandwich ELISA with two monoclonal antibodies highly specific for Tumor M2-PK. The ELISA kit is based on a microtiter plate (96 well format) with 12 single strips x 8 wells suitable for up to 42 samples in duplicate.

Sample Material

Human EDTA Plasma only.

Samples may be stored up to 3 days at 4° - 8° C or for up to 1 year at -20°C.



Reference Concentration

- ≤ 15.0 U/ml in EDTA Plasma
- A reference concentration of ≤ 15.0 U/ml in EDTA Plasma 15.0 U Tumor M2-PK/ml corresponds to a specificity of 90% in a control group with diseases other than tumor (n=393).
- Values in a range of 15-20 U/ml represent the „grey zone".

Please send me further information about your products

☐ **ScheBo® • Pancreatic Elastase 1** *Stool Test*
Non-invasive test for the diagnosis of exocrine pancreatic insufficiency due to
Chronic Pancreatitis
Cholelithiasis
Cystic Fibrosis
Diabetes Mellitus
Papillary Stenosis
Pancreatic Tumor

☐ **ScheBo® • Pancreatic Elastase 1** *Serum Test*
Specific and stable laboratory parameter for the diagnosis or exclusion of acute Pancreatitis, ECRP- or gallstone-induced Pancreatitis.

☐ **ScheBo® • Tumor M2-PK** *EDTA-Plasma Test*
The first biomarker, wich detects a metabolic state specific for a variety of tumors

☐ **ScheBo® • Tumor M2-PK** *Stool Test*
Metabolic biomarker for colorectal cancer screening.
Independent of faecal occult blood (FOB)

☐ I am interested in an introductory offer

☐ Please contact me

Reply Fax

Head office ++49(0)641-4996-77

UK & Republic of Ireland ++44(0)1256-327889

Name/Title
☐ Female ☐ Male

Hospital/Institute/Company

Department

Street

Postcode/City

Country

Phone

Fax

Email